What is the preferred treatment between propylthiouracil (PTU) and methimazole for a patient with hyperthyroidism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Methimazole vs PTU in Hyperthyroidism

Methimazole is the preferred first-line antithyroid drug for hyperthyroidism due to superior efficacy and safety profile, with the critical exception of the first trimester of pregnancy when propylthiouracil (PTU) must be used. 1

Drug Selection Algorithm

Non-Pregnant Patients

  • Methimazole is the drug of choice for all non-pregnant patients with hyperthyroidism 1
  • PTU is reserved exclusively for patients who are intolerant to methimazole 2
  • PTU carries a black box warning for severe liver injury and acute liver failure, including cases requiring liver transplantation in both adults and children 2

Pregnant Patients

  • First trimester (weeks 0-13): PTU is mandatory due to methimazole's association with congenital malformations including aplasia cutis and choanal/esophageal atresia 1, 3, 4
  • Meta-analysis confirms PTU has lower risk of congenital anomalies compared to MMI (OR 0.80,95%CI 0.69-0.92) 5
  • Second and third trimesters: Switch to methimazole to avoid PTU's hepatotoxicity risk 3
  • Goal is maintaining free T4 in the high-normal range using the lowest possible dose 1, 6

Pediatric Patients

  • Methimazole is strongly preferred in children due to postmarketing reports of severe liver injury with PTU 3

Safety Profile Comparison

Hepatotoxicity

  • PTU causes significantly more liver injury than methimazole (OR 2.40,95%CI 1.16-4.96) 7
  • PTU elevates transaminases much more frequently (OR 3.96,95%CI 2.49-6.28) 7
  • PTU hepatotoxicity can be fatal and may require liver transplantation 2

Other Adverse Effects

  • No significant difference in agranulocytosis, rash, or urticaria between the two drugs 7
  • Both drugs require monitoring for agranulocytosis (typically within first 3 months), presenting as sore throat and fever requiring immediate CBC and drug discontinuation 1

Birth Defects

  • Methimazole has higher odds of birth defects in first trimester (OR 1.29,95%CI 1.09-1.53) 7
  • Switching between MMI and PTU during pregnancy does not reduce birth defect risk compared to PTU alone 5

Dosing and Administration

Methimazole

  • Starting dose: 10-30 mg as single daily dose 4
  • Can be administered once daily (major advantage over PTU) 4
  • Less expensive and more widely available 4

PTU

  • Starting dose: 100-300 mg every 6 hours (requires multiple daily doses) 4
  • More frequent dosing reduces compliance 4

Monitoring Strategy

  • Monitor free T4 or free T3 index every 2-4 weeks during initial treatment 1
  • Critical pitfall: Target is high-normal free T4/T3, NOT normalized TSH (which may remain suppressed for months) 1
  • Do not reduce dose based solely on suppressed TSH while free T4 remains elevated 1

Breastfeeding

  • Both methimazole and PTU are compatible with breastfeeding 6, 3
  • No contraindications for either drug during lactation 4

Common Clinical Pitfall

The most dangerous error is using methimazole in the first trimester of pregnancy or continuing PTU beyond the first trimester when methimazole would be safer. Always verify pregnancy status before initiating methimazole and switch to methimazole after week 13 of gestation. 3, 2

References

Guideline

Treatment of Hyperthyroidism with Antithyroid Drugs

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Antithyroid drugs therapy].

La Clinica terapeutica, 2009

Guideline

Hyperthyroidism Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

SIDE EFFECTS OF PTU AND MMI IN THE TREATMENT OF HYPERTHYROIDISM: A SYSTEMATIC REVIEW AND META-ANALYSIS.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2020

Related Questions

What is the preferred treatment between propylthiouracil (PTU) and methimazole for a pregnant woman with hyperthyroidism?
What are the recommended antithyroid drugs (ATDs) for managing hyperthyroidism?
What is the most likely treatment for a pregnant woman in her 2nd trimester (14 weeks gestation) with symptoms of hyperthyroidism, including tremors, palpitations, and right neck swelling?
What is the difference between Propylthiouracil (PTU) and Carbimazole in treating hyperthyroidism?
What is the recommended first-line treatment for hyperthyroidism according to the Philippine Clinical Practice Guidelines (CPG)?
What is the prognosis for a patient with a history of diabetes and possible cancer, presenting with lymphedema and neuropathy in the left leg and foot, who has developed E. coli bacteremia and an infected callus, and is being treated with intravenous (IV) antibiotics, such as cefepime or piperacillin-tazobactam, after undergoing a computed tomography (CT) perfusion study and magnetic resonance imaging (MRI) to assess the extent of the infection?
Can potassium citrate be taken on an empty stomach in patients with a history of kidney stones or hypocitraturia?
What is the best treatment approach for an elderly non-diabetic patient with E. coli bacteremia and an infected callus, considering potential impaired renal function and existing lymphedema and neuropathy?
How will E. coli bacteremia, an infected callus, lymphedema, and neuropathy impact a scheduled knee replacement surgery in 1.5 months?
What is the best management plan for an elderly female patient with a history of hypertension (high blood pressure), hyperlipidemia (elevated lipids), gastroesophageal reflux disease (GERD), and type 2 diabetes mellitus, who recently experienced a left middle cerebral artery (MCA) stroke, and is currently presenting with post-stroke spasticity, nutritional decline, mood and anxiety symptoms, electrolyte abnormalities, and abnormal liver enzymes?
How do you define combination chemotherapy-based regimens for various cancer types and patient populations?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.